Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker

Background: Minimal residual disease (MRD) tests provide early identification of hematologic relapse and timely management of acute myeloid leukemia (AML) patients. Approximately, 50% of AML patients do not have clonal chromosomal aberrations and categorize as a cytogenetically normal acute myeloid...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Hematol Oncol Stem Cell Res
Egile Nagusiak: Alizad Ghandforoush, Nasrin, Chahardouli, Bahram, Rostami, Shahrbano, Ghadimi, Habibeh, Ghasemi, Ali, Alimoghaddam, Kamran, Ghavamzadeh, Ardeshir, Nadali, Fatemeh
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4969559/
https://ncbi.nlm.nih.gov/pubmed/27489590
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak